დასაწყისი · კატალოგი · პროფილი · ცხრილი
სკრინინგი BODY HANDBOOK
სკრინინგი · §125
HPV Vaccine: Adult Catch-Up
If you missed the HPV shot as a teenager, the FDA approved you for it through age 45 in 2018 — but the CDC stopped short of calling it routine, instead telling clinicians to "have a conversation." The catch: even after years of sexual activity, you are probably still naive to most of the nine HPV types the vaccine covers, and the catch-up trial in adults 24–45 hit 88.7% efficacy against vaccine-type pre-cancer and warts. The payoff is six cancers prevented at the long horizon, no genital warts at the short one, and three sore arms in between. Whether the math works for you depends on what your next decade of partner exposure looks like.
გადაწყვიტე · კურსი მტკიცებულება ზომიერი თავი სკრინინგი

A bounded course: three shots over six months, then done forever. The list price stings if you are uninsured (~$1,089), but commercial insurance usually covers it. The longevity payoff is real but smaller than vaccinating at 12 — most of the lifetime exposure has already happened. The decision turns on one question: how much new sexual exposure is plausibly ahead of you?

The vaccine teaches your immune system to recognise the outside of nine HPV strains — six that cause most cervical, anal, throat, and other HPV-driven cancers, and two more that cause about 90% of genital warts. It is a shell, not the virus: no DNA inside, no chance of giving you HPV. The shell looks enough like the real virus that you build antibodies that swarm any actual HPV particle before it can get into your cells.

The thing that surprises people about catch-up: this is not "either you were exposed or you weren't." It is type-by-type. There are nine strains in the vaccine, and you have to have already caught a specific strain for the vaccine to do nothing about that strain. Most adults, even with a long partner history, are still naive to most of the nine — the per-encounter, type-specific transmission rate is the relevant unit, not your total number of partners. The vaccine cannot clear an infection you already have. It cannot erase warts you already have. It can only block the strains you have not picked up yet, which for most people is still most of them.

Does it actually work this late?

Yes — the catch-up evidence is the best part of the case. The pivotal adult trial randomised 3,819 women aged 24–45 and tracked them for four years. Among the ones who completed the series and were naive to the vaccine strains going in, the vaccine prevented 88.7% of vaccine-type pre-cancer and genital lesions and roughly 99% of vaccine-type genital warts. The number drops to about 47% if you include the women who were already infected when they enrolled — which is exactly what a prophylactic shot looks like: it cannot rescue strains you already carry, only block the rest.

At population scale, the Swedish national register followed 1.67 million women and found cervical cancer rates dropped by 63% in vaccinated women overall — and by nearly 88% in the ones vaccinated before age 17 Lei et al. 2020. The England programme analysis found the same pattern: huge effect in the youngest cohorts, real-but-smaller effect in the older catch-up cohorts Falcaro et al. 2021. For men, the cleanest direct trial enrolled men who have sex with men and showed the vaccine prevented 75% of anal pre-cancer caused by vaccine strains Palefsky 2011. A 2024 US cohort comparing vaccinated to unvaccinated adults under 40 found HPV-related cancers in vaccinated men dropped by more than half, driven mostly by head-and-neck cancers Saxena et al. 2024.

One trial points the other way and is worth naming. In HIV-positive adults aged 27+, the vaccine failed to prevent new anal HPV infection — the population with the highest baseline cancer risk, where you would predict the biggest benefit, got none Wilkin 2018. The likely reason: by 27, this group's cumulative exposure to most of the nine strains was already too high for "block the rest" to leave much rest. That is the catch-up question in miniature — how much of your lifetime exposure is already behind you.

What you are actually preventing

The cancers HPV causes do not lurk in the corners of medicine. Cervical cancer kills more than 4,000 American women a year. Throat cancer is the fastest-rising cancer in middle-aged American men and HPV is the engine behind it — incidence is still climbing, with the peak burden projected for the mid-2030s Damgacioglu 2022. Anal cancer, vulvar cancer, vaginal cancer, penile cancer — they are individually rarer but they all run on the same handful of HPV strains, and one shot programme covers all of them.

The thing you might catch first, though, is genital warts. They are not subtle. They show up months after exposure, they require burning or freezing or cutting off, and they come back. Annual incidence is roughly one in a hundred sexually active adults. The vaccine prevents the strains that cause about 90% of them Castellsague 2011.

The honest reframe: the cancer payoff is large in absolute terms over the decades but the marginal payoff from getting vaccinated at 35 instead of 12 is smaller — because much of the lifetime exposure has already happened. Throat cancer in men is the partial exception. That clock runs 20–30 years from exposure to diagnosis, and if you are 35 a lot of that window is still ahead of you.

Who this is most worth it for

The case sharpens at the edges. If any of the following describes your next decade, the math leans toward yes:

  • You are newly single, recently divorced, or about to be — new partners ahead means new strain exposure ahead.
  • You are a man who has sex with men. Baseline anal-cancer risk is many times the population average, and the vaccine is the only prevention tool that exists.
  • You are about to go on immunosuppression — pre-transplant, planned chemo, an autoimmune regimen — and want the antibody response while your immune system can still build one.
  • Your partner count to date has been low, which makes you more likely to still be naive to most of the nine strains.

The case dulls if you are in a long-term mutually monogamous relationship with no new exposure plausibly ahead, or if you have had documented HPV-related disease from multiple vaccine strains and the room left for "block the rest" has shrunk.

How to get it

Walk into a primary-care office or a pharmacy. The whole programme is three quick injections in the upper arm at month 0, month 2, and month 6. Pharmacies in most states administer it without a doctor's referral. If you miss a dose, you do not restart — you just complete the series late. There is no booster after the three doses.

What it costs

The list price is roughly $363 per shot, about $1,089 for the full series — that is the number you face if you walk in uninsured at full retail. Almost every US commercial insurance plan covers Gardasil 9 with no copay; Medicare Part D usually covers it. The catch in the catch-up band is that ACA preventive-care coverage is mandated only through age 26 — past that, payers vary, some require a documented clinical indication, and a phone call to your insurer before booking is worth its weight. Merck runs a patient-assistance programme that gives the vaccine free to uninsured adults 19–45 meeting income criteria.

When not to

Where this goes wrong

Three failure patterns are common. People start the series and never finish — life gets in the way and dose three slips. Two doses confer noticeably less protection than three in this age group; the two-dose adolescent schedule is not validated past 14. Set the dose-three calendar reminder when you book dose one.

People get the shot, breathe a sigh of relief, and stop getting cervical screening. Do not. The vaccine prevents about 90% of HPV-driven cancer — not 100% — and the remaining strains still cause disease that Pap and HPV co-testing catch early CDC 2024.

People expect the shot to treat something they already have. It does not. If you have visible warts, an abnormal Pap, or a known HPV-positive lesion, vaccination does not treat those — and it will not make the existing strain go away. It will still protect against the other vaccine strains you have not picked up yet, which is usually most of them.

What changes after you finish

The fastest payoff lands inside weeks of dose three: your odds of catching new genital warts from a partner go to essentially zero for the two strains that cause about 90% of them Castellsague 2011. You will not feel this — you just stop being in the lottery for a problem that turns Tuesdays into dermatology appointments.

The cervical-screening payoff shows up in the 5-to-10-year window: fewer abnormal Paps, fewer colposcopies, fewer LEEP procedures to cut out pre-cancer Falcaro et al. 2021. The actual cancers — cervical, anal, throat, the rarer ones — take 15 to 30 years to show their reduced rates, and for throat cancer in men the population-level signal will not be visible in registry data until the mid-2030s Damgacioglu 2022. You do not see this one as it happens. The version of you at 60 just does not get the diagnosis the unvaccinated version did.

What to look at next

Cervical cancer screening (Pap and HPV co-testing) remains your job vaccinated or not — different substance, separate decision. Anal cancer screening becomes worth discussing if you are a man who has sex with men or living with HIV. If you have HPV-related lesions today, you are looking at treatment, not prevention — the vaccine does not heal what is already there.

დაკავშირებული სახელმძღვანელოში
ეხმარება
  • — The shot blocks the virus; screening catches what slips through — you want both, not one.
დაკავშირებული
  • — The shot prevents the HPV cancers; the screening schedule is how you catch the ones it can't fully cover — they work as a pair.
  • — This is the adult catch-up version of a shot most people miss — it slots into the broader vaccine schedule.
  • — If you're catching up on HPV, check whether the shingles and RSV shots are due too — both are big.
·
125